Calidi Biotherapeutics Q3 2026 net loss narrows 67% to $3.6 million
CLDI•Calidi Biotherapeutics’ third-quarter 2026 net loss attributable to common stockholders narrowed 67% year over year to $3.6 million. Cash fell 30% to $3.9 million at September 30, while a restructuring is expected to save $3 million annually.
1. Quarterly results
General and administrative expenses fell 39% year over year to $1.6 million, while research and development spending rose 13% to $2.7 million. Cash was $3.9 million at September 30, 2026, down 30% from December 31, 2025.
2. Restructuring and research
A November 6 restructuring, predominantly through headcount reductions, is expected to save $3 million annually and extend operating runway. Lead candidate CLD-401 continued progressing toward the clinic; preclinical data showed complete tumor eradication in 80% of breast cancer tumor-bearing mice.
